Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal dominant osteopetrosis type I (ADO I) is a sclerosing bone disorder characterized by skeletal densification that predominantly involves the cranial vault.
Features include common findings: Calvarial osteosclerosis, Thickened cortex of long bones, and Torus palatinus; and sometimes findings: Mandibular pain and Headache. 13 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 7 | Calvarial osteosclerosis, Abnormality of the vertebral column, Osteopetrosis |
LRP5 encodes LDL receptor related protein 5 (1,615 aa). Acts as a coreceptor with members of the frizzled family of seven-transmembrane spanning receptors to transduce signal by Wnt proteins. Highest expression in Artery Aorta (83.2 TPM) and Artery Tibial (67.8 TPM).
Autosomal dominant osteopetrosis 1 is associated with mutations in the LRP5 gene on chromosome 11.
The LRP5 protein participates in LRP5 D666_L809del, Signaling by LRP5 mutants, and Negative regulation of TCF-dependent signaling by WNT ligand antagonists pathways.
LRP5 is classified as a druggable target with score 0.0.
Genetic testing for LRP5 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 3 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for autosomal dominant osteopetrosis 1.
12 publications have been identified in PubMed for autosomal dominant osteopetrosis 1. Research spans Case Report / Case Series (45%), Basic Science / Preclinical (18%), and Gene Therapy / Novel Therapeutics (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 45% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 12:51 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Lab test results
1 |
Elevated serum acid phosphatase |
Head and neck | 1 | Mandibular pain |
Ears | 1 | Conductive hearing impairment |
Brain and nerves | 1 | Headache |
Laboratory research
2 |
18% |
New treatment approaches | 2 | 18% |
Research summaries | 1 | 9% |
Clinical study results | 1 | 9% |
Bustos-Merlo A (2026). [PMID: 41505949](https://pubmed.ncbi.nlm.nih.gov/41505949/). *Med Clin (Barc)*. [Case Report / Case Series]
Sha Y (2025). [PMID: 40165215](https://pubmed.ncbi.nlm.nih.gov/40165215/). *BMC Biol*. [Basic Science / Preclinical]
Xu J (2025). [PMID: 39934917](https://pubmed.ncbi.nlm.nih.gov/39934917/). *Stem Cell Res Ther*. [Gene Therapy / Novel Therapeutics]
Liu M (2025). [PMID: 39994654](https://pubmed.ncbi.nlm.nih.gov/39994654/). *BMC Med Genomics*. [Case Report / Case Series]
Zhou R (2025). [PMID: 39930640](https://pubmed.ncbi.nlm.nih.gov/39930640/). *J Clin Endocrinol Metab*. [Clinical Trial Publication]
Lopez-Aldazabal V (2025). [PMID: 40833355](https://pubmed.ncbi.nlm.nih.gov/40833355/). *Vet Med Sci*. [Case Report / Case Series]
Bae S (2025). [PMID: 41431003](https://pubmed.ncbi.nlm.nih.gov/41431003/). *Medicine (Baltimore)*. [Case Report / Case Series]
Saffie-Siebert S (2024). [PMID: 38733412](https://pubmed.ncbi.nlm.nih.gov/38733412/). *Calcif Tissue Int*. [Gene Therapy / Novel Therapeutics]
Jodeh W (2024). [PMID: 38261998](https://pubmed.ncbi.nlm.nih.gov/38261998/). *J Clin Endocrinol Metab*. [Case Report / Case Series]
Sandal S (2024). [PMID: 39359949](https://pubmed.ncbi.nlm.nih.gov/39359949/). *Mol Syndromol*. [Basic Science / Preclinical]